Based on the strength of our target and drug technologies and expertise, we have established collaborations with pharmaceutical and biotechnology and companies.  The below examples illustrate the range of services and products we provide to our partners.

Amgen

BioFocus DPI expanded and extended its longstanding drug discovery collaboration with Amgen through 2007 and 2008. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply biologically-directed library compounds to Amgen’s discovery programs.

Athrogen

In 2006, BioFocus BioFocus DPI entered into a three-year target discovery alliance with Arthrogen BV. The alliance focuses on identifying and validating novel targets for gene therapy applications in rheumatoid arthritis.

AstraZeneca

In August 2006, BioFocus DPI entered a new drug discovery collaboration with AstraZeneca. BioFocus DPI will perform hit-to-lead medicinal chemistry services for AstraZeneca’s respiratory and inflammatory drug discovery programs.

Cellzome

BioFocus DPI initiated a kinase drug discovery collaboration with Cellzome in July 2006, giving the Cellzome access to its SoftFocus^® kinase libraries and providing biological screening and chemistry expertise to find inhibitors of Cellzome’s kinase targets.

GlaxoSmithKline

In 2005 GlaxoSmithKline licensed targets from Galapagos’ asthma program and entered into a three-year target discovery alliance to discover targets that are disease modifying in asthma and inflammatory diseases.

LEO Pharma

BioFocus DPI is using a subset of its natural compound collection for high throughput screening, hit verification, and profiling of selected compounds for LEO Pharma’s antibacterial research program.

Roche